GlassScriptPhysician profile
Maegan Lazo
NPI 1578320644
$4,292.76
in general payments reported to CMS, 2019-2025
19 companies · $2,030 in 2025
The $2,030 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,263 · 2025: $2,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,203 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,202.77 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,303.51 | 2024-2025 | Briviact, Fintepla, Nayzilam |
| Jazz Pharmaceuticals INC. | $916.49 | 2024-2025 | |
| Aucta Pharmaceuticals, INC. | $382.96 | 2024-2025 | Motpoly Xr |
| Neurelis, INC. | $354.42 | 2024-2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $243.26 | 2024-2025 | |
| Tris Pharma INC | $230.28 | 2024-2025 | Dyanavel Xr, Onyda Xr, Quillivant |
| Collegium Pharmaceutical, INC. | $149.08 | 2025 | Jornay Pm |
| Sk Life Science, INC. | $139.75 | 2024-2025 | |
| Ironshore Pharmaceuticals INC. | $135.57 | 2024 | |
| Corium, LLC | $89.65 | 2024-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $75.84 | 2025 | Qelbree |
| Aquestive Therapeutics, INC. | $50.11 | 2025 | |
| Janssen Biotech, INC. | $48.95 | 2025 | |
| Xeris Pharmaceuticals, INC. | $43.04 | 2025 | Keveyis |
| Noven Therapeutics, LLC | $41.76 | 2024-2025 | Xelstrym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $32.74 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Immedica Pharma US, INC. | $22.86 | 2024 | |
| Acadia Pharmaceuticals INC | $17.00 | 2025 | Daybue |
| Vertical Pharmaceuticals, LLC | $15.49 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maegan Lazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.